News for Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia’s declining revenues. See why I reiterate my buy rating for AKBA stock.

PR NewswireCAMBRIDGE, Mass., Jan. 2, 2025 CAMBRIDGE, Mass., Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical co

PR NewswireCAMBRIDGE, Mass., Dec. 3, 2024 CAMBRIDGE, Mass., Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical co

PR NewswireCAMBRIDGE, Mass., Dec. 3, 2024 Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current stan

PR NewswireCAMBRIDGE, Mass., Nov. 25, 2024 CAMBRIDGE, Mass., Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical

Akebia Therapeutics expands market share with strong Q3 results. See why AKBA stock is gaining momentum, despite potential competition post-2025.

Total Revenue: $37.4 million in Q3 2024, down from $42 million in Q3 2023.AURYXIA Net Product Revenue: $35.6 million in Q3 2024, compared to $40.1 million in Q

Nov 07, 2024 / 01:00PM GMTOperator Good day. And thank you for standing by. Welcome to the Akebia's third quarter, 2024 financial results conference call at thi

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ETCompany ParticipantsMercedes Carrasco - Senior Director,...

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -100% and 18.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

The market for medications for chronic kidney disease (CKD) is growing due to an increase in the prevalence of CKD....

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...

Akebia Therapeutics appoints new CFO

Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results.

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

Newark, New Castle, USA, March 16, 2023 (GLOBE NEWSWIRE) -- According to the deep-dive market assessment study by Growth Plus Reports, the global chronic...

Acute Respiratory Distress Syndrome Therapeutics Market by Drug Class (Bronchodilators, Corticosteroids, Antimicrobial Agents, and Other Drug Class) and by...

Penny stocks under $1 to watch this week.